Intact N-Terminal Propeptide of Type 1 Procollagen
Approximately 90% of bone and tissue consists of type 1 collagen. Collagen is a group of proteins that mesh together and strengthen the bone structure. Type 1 collagen is derived from type 1 procollagen, which has two propeptides (C-terminal and N-terminal) on each end of its molecule. Certain proteases will react with the propeptides and cleave the terminal ends from the molecule before they are assembled into collagen fibers. The rate of synthesis of type I collagen can be determined by measuring C-terminal (PICP) and N-terminal (PINP) propeptides. Measurements of both PICP and PINP are both biologically valuable, but changes in PINP are more dramatic and less influenced by other sources such as hormones. Increased levels can indicate normal growth as well as bone disease. Bone disease is characterized by imbalance in bone turnover that occurs when there is a disorder in formation and resorption.
PINP is one of the most often used markers and indicators of bone formation, and is mostly used for monitoring bone formation therapies and antiresorptive therapies. PINP is very useful in monitoring osteoporosis as it can monitor bone turnover and metabolism. Although bone density measurement is the gold standard in osteoporosis diagnosis, PINP measurement can aid in determination of severity of disease. Pre- and post-levels can determine success in bone formation therapy or antiresorptive therapy. PINP has also been valuable in assessing bone metastases in certain malignancies and assessing type I collagen turnover in Paget’s disease of the bone. Decreased levels of PINP can be seen in acute bone turnover suppression in renal disease or adynamic bone disease.
- Detects increased bone turnover - used to identify patients at risk of fracture
- Helps to monitor antiresorptive and anabolic therapy in patients with osteoporosis
- As an aid in diagnosis and management of osteoporosis
- Complements and correlates with bone mineral density measurement
- Assesses type 1 collagen turnover in Paget’s disease of the bone
- Assesses bone metastases in certain bone malignancies
Increased in:
- Normal growth
- Osteoporosis
- Paget’s Disease
- Healing fractures
- Hyperparathyroidism
Decreased in:
- Acute bone turnover suppression in oral glucose therapy
- Renal failure
- Adynamic bone disease
When using test to monitor osteoporosis therapy, recommend initial testing prior to beginning therapy and reevaluate 3-6 months after starting therapy.
Male:
22-87 μg/L
Female:
Premenopausal: 19-83 μg/L
Postmenopausal: 16-96 μg/L
Radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA).
Serum (SST or Red).
Separate serum immediately and keep frozen.
Stability
- Ambient: Unacceptable
- Refrigerated: Unacceptable
- Frozen: 60 days
Note: Collect all specimens at the same time of day, as there is a diurnal variation of PINP with values being higher at night.
- Bone Miner Res. 1999; 14(9):1614-21. [PMID: 10469291]
- J Clin Pharmacol. 2002; 42(3):190-6. [PMID: 11865965]
- Bone. 1998; 23(5):471-7. [PMID: 9823455]
- Scand J Clin Lab Invest. 2002; 62(3):237-43. [PMID: 12088343]
- Endes DB and Rude RK. “Mineral and Bone Metabolism.” Tietz Textbook of Clinical Chemistry, 3rd ed. Burtis CA, Ashwood ER (eds). Philadelphia, PA: WB Saunders Co, 1999, 1349-457.